関連する実験動画

Updated: Jul 29, 2026

Layer-by-layer Collagen Deposition in Microfluidic Devices for Microtissue Stabilization
09:56

Layer-by-layer Collagen Deposition in Microfluidic Devices for Microtissue Stabilization

Published on: September 29, 2015

カリウム塩化物製剤と糞便による血流. 10パーセントの溶液と,腸に塗料を塗らないワキシマトリックス錠剤を併用した並行研究

J A Rider, R J Manner, J I Swader

    JAMA
    |February 24, 1975
    PubMed
    まとめ

    胃腸の刺激を防ぐために設計された新しい塩化カリウム錠は,液体溶液と比較して,糞便の血流の有意な増加を示さなかった. これは,ワキシマトリックス錠剤がカリウム補給の安全な代替品であることを示唆しています.

    さらに関連する動画

    Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro10:25

    Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

    Published on: March 19, 2016

    Nondestructive Monitoring of Degradable Scaffold-Based Tissue-Engineered Blood Vessel Development Using Optical Coherence Tomography11:12

    Nondestructive Monitoring of Degradable Scaffold-Based Tissue-Engineered Blood Vessel Development Using Optical Coherence Tomography

    Published on: October 3, 2018

    関連する概念動画

    Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

    Antihypertensive Drugs: Potassium-Sparing Diuretics

    Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
    Drugs for Treatment of Diarrhea-Predominant IBS01:17

    Drugs for Treatment of Diarrhea-Predominant IBS

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
    Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
    Drugs for Treatment of Constipation-Predominant IBS01:21

    Drugs for Treatment of Constipation-Predominant IBS

    Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
    Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa01:22

    Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

    The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
    The pKa of a drug,...
    One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance00:56

    One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

    Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
    In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
    One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

    One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

    This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
    On...